Less than a year after speeding into the European Society of Cardiology's atrial fibrillation guidelines with a class 1 recommendation, the role of dronedarone (Multaq, Sanofi) in the treatment of AF ...

Please provide your email address to receive an email when new articles are posted on . “Despite this substantial clinical overlap and the recognition of AF as a potential therapeutic target in HF ...

Dronedarone is associated with a reduction in recurrent AF and may have other potential benefits. According to Richard L. Page, MD, president of the Heart Rhythm Society and a professor of medicine ...

SAN FRANCISCO, CA—Dronedarone use resulted in lower all-cause mortality compared with other antiarrhythmic drugs with no increased risk of cardiovascular-related deaths/ hospitalizations observed in ...

Boston, MA - Dronedarone (Sanofi-Aventis)—dubbed the "son of amiodarone"—is better than placebo at maintaining sinus rhythm in patients with atrial fibrillation (AF) and at reducing ventricular rate ...

Discover comprehensive details about Dronedarone, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Two phase 3 trials of dronedarone, a novel class III antiarrhythmic agent currently in development worldwide, have demonstrated that the drug is safe and effective for the maintenance of normal sinus ...

In a new article published in Acta Pharmaceutica Sinica B, authors Aneesh V. Karkhanis, Gopalakrishnan Venkatesan, Ryuichi Kambayashi, Atsushi Sugiyama, Eric Chun Yong Chan and colleagues from the ...

Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation. It also lowers heart rate and blood pressure and has antiadrenergic and potential ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of dronedarone, having considered evidence on the nature of atrial fibrillation and the value placed on the ...